Pages that link to "Q26765402"

The following pages link to Epigenetic regulators and their impact on therapy in acute myeloid leukemia (Q26765402):

Displaying 17 items.

• Emerging therapies for acute myeloid leukemia (Q33576363) (← links)
• Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells (Q33761948) (← links)
• The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia (Q37629537) (← links)
• Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers (Q38637354) (← links)
• Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma (Q39137683) (← links)
• RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia (Q41545370) (← links)
• A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators (Q42764236) (← links)
• Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist (Q46246849) (← links)
• Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). (Q54964566) (← links)
• Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. (Q55433291) (← links)
• Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia (Q57492375) (← links)
• [The aberrant epigenetic regulation and epigenomic landscape alteration in human acute myelogenous leukemia and the emerged agents that target epigenetic regulators]. (Q64946937) (← links)
• [Histone modification aberrations in acute myeloid leukemia and the target therapy development in clinical settings] (Q88121008) (← links)
• BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors (Q88230585) (← links)
• PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease (Q90458178) (← links)
• Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels (Q92073825) (← links)
• Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology (Q92258777) (← links)